Unknown

Dataset Information

0

PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.

ABSTRACT: Positive allosteric modulators (PAMs) of the M1 subtype of muscarinic acetylcholine receptor have attracted intense interest as an exciting new approach for improving the cognitive deficits in schizophrenia and Alzheimer's disease. Recent evidence suggests that the presence of intrinsic agonist activity of some M1 PAMs may reduce efficacy and contribute to adverse effect liability. However, the M1 PAM PF-06827443 was reported to have only weak agonist activity at human M1 receptors but produced M1-dependent adverse effects. We now report that PF-06827443 is an allosteric agonist in cell lines expressing rat, dog, and human M1 and use of inducible cell lines shows that agonist activity of PF-06827443 is dependent on receptor reserve. Furthermore, PF-06827443 is an agonist in native tissue preparations and induces behavioral convulsions in mice similar to other ago-PAMs. These findings suggest that PF-06827443 is a robust ago-PAM, independent of species, in cell lines and native systems.

SUBMITTER: Moran SP 

PROVIDER: S-EPMC6146053 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.

Moran Sean P SP   Cho Hyekyung P HP   Maksymetz James J   Remke Daniel H DH   Hanson Ryan M RM   Niswender Colleen M CM   Lindsley Craig W CW   Rook Jerri M JM   Conn P Jeffrey PJ  

ACS chemical neuroscience 20180425 9

Positive allosteric modulators (PAMs) of the M<sub>1</sub> subtype of muscarinic acetylcholine receptor have attracted intense interest as an exciting new approach for improving the cognitive deficits in schizophrenia and Alzheimer's disease. Recent evidence suggests that the presence of intrinsic agonist activity of some M<sub>1</sub> PAMs may reduce efficacy and contribute to adverse effect liability. However, the M<sub>1</sub> PAM PF-06827443 was reported to have only weak agonist activity at  ...[more]

Similar Datasets

Unknown The δ-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist.
| S-EPMC6514288 | biostudies-literature
Unknown The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain.
| S-EPMC4959951 | biostudies-literature
Transcriptomics REPROGRAMMING CBX8-PRC1 FUNCTION WITH A POSITIVE ALLOSTERIC MODULATOR
2022-01-03 | GSE182592 | GEO
Unknown Allosteric modulator potentiates β2AR agonist-promoted bronchoprotection in asthma models.
| S-EPMC10503797 | biostudies-literature
Unknown Pharmacology in translation: the preclinical and early clinical profile of the novel ?2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.
| S-EPMC5786456 | biostudies-literature
Unknown Reprogramming CBX8-PRC1 function with a positive allosteric modulator.
| S-EPMC9035045 | biostudies-literature
Unknown Mechanism of ?2AR regulation by an intracellular positive allosteric modulator.
| S-EPMC6705129 | biostudies-literature
Unknown Deconstruction of the α4β2 nicotinic acetylcholine receptor positive allosteric modulator desformylflustrabromine.
| S-EPMC3200116 | biostudies-literature
Unknown PTK7 is a positive allosteric modulator of GPR133 signaling in glioblastoma.
| S-EPMC10445595 | biostudies-literature
Unknown In Silico Identification and Experimental Validation of (-)-Muqubilin A, a Marine Norterpene Peroxide, as PPARα/γ-RXRα Agonist and RARα Positive Allosteric Modulator.
| S-EPMC6410278 | biostudies-literature